Clinical Trial

Evaluating the Efficacy and Safety of of HSK44459 in Patients With Behçet's Disease

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 30, 2025 (before its estimated June 5, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a phase 2, multi-center, randomised, double-blind, placebo-controlled study with an equal randomization among the HSK44459 dose 1, dose 2 and placebo treatment groups. The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.
Trial Details
NCT Number NCT06902428
Lead Sponsor Haisco Pharmaceutical Group Co., Ltd.
Conditions Behcet's Disease
Enrollment 120 participants
Start Date 2025-03-24
Primary Completion 2026-06-05 (estimated)
Study Completion 2026-07-03 (estimated)
Updated on ClinicalTrials.gov 2025-03-30